What You Should Know:
– Anumana, an AI-powered health technology company, has announced the strategic appointment of Harry S. Palmin as their new Chief Financial Officer (CFO).
– Palmin brings a wealth of experience to Anumana, boasting over 25 years in building, financing, and operating life sciences companies.
– In addition to his duties at Anumana, Palmin will also serve as CFO of Ventures for nference, a company of which Anumana is a portfolio company.
Leading Financial Operations and Growth Strategy
As CFO, Palmin will play a key role in Anumana’s executive leadership team. His responsibilities encompass:
- Overseeing financial operations
- Managing investor relations
- Spearheading corporate development activities
- Guiding the company’s strategic growth initiatives
Palmin Bio/Background
Palmin’s distinguished career includes tenure as CFO at Acer Therapeutics Inc., where he played a pivotal role in the company’s successful acquisition by Zevra Therapeutics, Inc. His leadership was instrumental in Acer’s public offering and the company’s FDA approval for OLPRUVATM, a treatment for urea cycle disorders. Prior to his role at Acer, Palmin served in multiple executive positions at Novelos Therapeutics, Inc., where he helped transform the company from conceptual stage into a leading public oncology and infectious disease development entity.
“Anumana is one of the most innovative companies in healthcare technology and it is an honor to be joining the organization at such a pivotal time in its growth,” said Palmin. “The progress Anumana has accomplished in just three years since its founding and the potential impact that Anumana’s AI technology platform can make on patient outcomes are inspiring. I am excited to be part of the team and the mission to use pioneering AI technology to unlock the electrical language of the heart and improve patient care.”
